EntryPoint Capital LLC Invests $436,000 in Mirum Pharmaceuticals, Inc. $MIRM

Key Points

• EntryPoint Capital LLC invested $436,000 in Mirum Pharmaceuticals, acquiring 9,675 shares, as reported in their recent SEC filing.
• Multiple hedge funds have increased their stakes in Mirum Pharmaceuticals, with notable increases from Vanguard Group Inc. (4.8%) and Nuveen Asset Management LLC (46.7%) in the last quarter.
• Mirum Pharmaceuticals received a consensus rating of "Buy" from analysts, with an average target price of $74.13 and recent upgrades from multiple research firms.

EntryPoint Capital LLC bought a new position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 9,675 shares of the company's stock, valued at approximately $436,000.

A number of other institutional investors have also recently added to or reduced their stakes in MIRM. CWM LLC grew its holdings in Mirum Pharmaceuticals by 259.4% during the 1st quarter. CWM LLC now owns 593 shares of the company's stock worth $27,000 after acquiring an additional 428 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Mirum Pharmaceuticals in the 4th quarter worth approximately $35,000. GF Fund Management CO. LTD. acquired a new position in shares of Mirum Pharmaceuticals in the 4th quarter worth approximately $42,000. KBC Group NV acquired a new position in shares of Mirum Pharmaceuticals in the 1st quarter worth approximately $89,000. Finally, Summit Investment Advisors Inc. lifted its position in shares of Mirum Pharmaceuticals by 8.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company's stock worth $172,000 after purchasing an additional 312 shares during the period.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, CEO Christopher Peetz sold 40,000 shares of the company's stock in a transaction on Monday, August 11th. The shares were sold at an average price of $62.00, for a total value of $2,480,000.00. Following the completion of the sale, the chief executive officer owned 138,641 shares in the company, valued at $8,595,742. This represents a 22.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Jolanda Howe sold 10,000 shares of the company's stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $58.00, for a total transaction of $580,000.00. Following the completion of the sale, the senior vice president owned 2,426 shares of the company's stock, valued at approximately $140,708. The trade was a 80.48% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 91,041 shares of company stock valued at $5,320,624. Company insiders own 14.36% of the company's stock.

Mirum Pharmaceuticals Stock Up 1.0%

MIRM traded up $0.73 during trading on Tuesday, hitting $72.54. 238,569 shares of the company's stock were exchanged, compared to its average volume of 507,112. The company has a quick ratio of 2.97, a current ratio of 3.13 and a debt-to-equity ratio of 1.21. The business's 50 day moving average is $55.24 and its two-hundred day moving average is $48.54. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $36.86 and a fifty-two week high of $72.47. The stock has a market cap of $3.64 billion, a P/E ratio of -59.95 and a beta of 0.94.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.19. Mirum Pharmaceuticals had a negative net margin of 13.65% and a negative return on equity of 24.76%. The firm had revenue of $127.79 million for the quarter, compared to the consensus estimate of $107.91 million. During the same quarter in the prior year, the company posted ($0.52) earnings per share. The business's revenue was up 64.1% on a year-over-year basis. As a group, equities analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

MIRM has been the topic of a number of recent analyst reports. Stifel Nicolaus set a $89.00 price target on shares of Mirum Pharmaceuticals and gave the stock a "buy" rating in a research report on Monday, August 11th. Evercore ISI boosted their target price on shares of Mirum Pharmaceuticals from $77.00 to $89.00 and gave the company an "outperform" rating in a research report on Friday, August 8th. HC Wainwright boosted their target price on shares of Mirum Pharmaceuticals from $73.00 to $80.00 and gave the company a "buy" rating in a research report on Thursday, August 7th. Raymond James Financial reiterated a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research report on Thursday, August 7th. Finally, JMP Securities set a $81.00 target price on shares of Mirum Pharmaceuticals and gave the company a "market outperform" rating in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company. Based on data from MarketBeat.com, Mirum Pharmaceuticals presently has a consensus rating of "Buy" and a consensus target price of $74.13.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.